SS
ADIL

SBI Securities’s Adial Pharmaceuticals ADIL Stock Holding History

SBI Securities’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84 Buy
47
+1
+2% +$4 ﹤0.01% 3453
2025
Q4 		$255 Sell
46
-10
-18% -$81 ﹤0.01% 3135
2025
Q3 		$493 Buy
56
+3
+6% +$29 ﹤0.01% 2972
2025
Q2 		$398 Buy
53
+16
+43% +$242 ﹤0.01% 3055
2025
Q1 		$588 Hold
37
– – ﹤0.01% 2805
2024
Q4 		$946 Buy
+37
New +$963 ﹤0.01% 2633

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SBI Securities's ADIL Position: Q1 2026 in Review

SBI Securities increased its Adial Pharmaceuticals (ADIL) stake by 2.2% in Q1 2026, buying an estimated $4 and bringing the position to 47 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #3453.

SBI Securities first reported a position in ADIL in Q4 2024 and has held it in 6 quarters since. The position peaked at $946 in Q4 2024. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • SBI Securities held 47 shares of Adial Pharmaceuticals worth $84 as of Q1 2026.
  • SBI Securities bought 1 Adial Pharmaceuticals share in Q1 2026, an estimated $4.
  • Adial Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3453 holding.
  • SBI Securities first reported a position in Adial Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Adial Pharmaceuticals position peaked at $946 in Q4 2024.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.